EMG
NERV icon

Ellington Management Group’s Minerva Neurosciences NERV Stock Holding History

Ellington Management Group’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,225
Closed -$127K – 689
2019
Q4 		$127K Buy
+2,225
New +$98.1K 0.03% 482
2017
Q4 		– Sell
-1,738
Closed -$106K – 739
2017
Q3 		$106K Buy
1,738
+400
+30% +$22.9K 0.02% 587
2017
Q2 		$95K Buy
+1,338
New +$86.6K 0.01% 601

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
IVAI
Index Venture Associates IV St. Helier, Channel Islands, Jersey $6.24M AUM
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ellington Management Group's NERV Position: Q1 2020 in Review

Ellington Management Group sold out of Minerva Neurosciences (NERV) in Q1 2020, closing a stake of 2,225 shares — an estimated $127K sold.

Ellington Management Group first reported a position in NERV in Q2 2017 and held it in 3 quarters. The position peaked at $127K in Q4 2019. 90 funds tracked by Wall St. Rank hold NERV as of Q1 2020.

  • Ellington Management Group reported no remaining Minerva Neurosciences position as of Q1 2020 after selling out during the quarter.
  • Ellington Management Group sold 2,225 Minerva Neurosciences shares in Q1 2020, an estimated $127K.
  • Ellington Management Group first reported a position in Minerva Neurosciences in Q2 2017 and held it in 3 quarters.
  • Ellington Management Group's Minerva Neurosciences position peaked at $127K in Q4 2019.
  • 90 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2020.

Based on Ellington Management Group's 13F filing for Q1 2020, filed 15 May 2020.